Evidence map›Paper›PMID 41219537›Full record

ArticleEMBO molecular medicine2025

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.

Irene Ballesteros-González, Iván Hernández-Navas, Oksana Brehey, Carmen G Lechuga, Marina Salmón, Morena Scotece, Ricardo Velasco-Vicente, Alejandra A Flores-Gómez, Antonio Cebriá, Lucía Simón-Carrasco and 13 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Irene Ballesteros-GonzálezMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007, Salamanca, Spain.
Iván Hernández-NavasGrupo de Terapias Dirigidas para la Oncología de Precisión & Unidad de Investigación Clínica de Cáncer de Pulmón, Instituto de Investigación Hospital 12 de Octubre, 28041, Madrid, Spain.
Oksana BreheyTumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Carmen G LechugaTumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Marina SalmónTumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Morena ScoteceMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007, Salamanca, Spain.
Ricardo Velasco-VicenteMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007, Salamanca, Spain.
Alejandra A Flores-GómezMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007, Salamanca, Spain.
Antonio CebriáExperimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Lucía Simón-CarrascoTumor Biology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-3281-8144
Gerardo JiménezInstituto de Biología Molecular de Barcelona (IBMB), CSIC, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2765-9289
Monica MusteanuCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Carmen GuerraCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Orlando DomínguezGenomics Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Eduardo CaleirasHistopathology Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Carmen Blanco-AparicioExperimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.ORCID http://orcid.org/0000-0002-3249-6595
Tirso PonsDepartment of Immunology and Oncology, National Center for Biotechnology (CNB-CSIC), Spanish National Research Council, 28049, Madrid, Spain.
Irene FerrerGrupo de Terapias Dirigidas para la Oncología de Precisión & Unidad de Investigación Clínica de Cáncer de Pulmón, Instituto de Investigación Hospital 12 de Octubre, 28041, Madrid, Spain.
Luis Paz-AresCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Raul Torres-RuizMolecular Cytogenetics and Genome Editing Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.ORCID http://orcid.org/0000-0001-9606-0398
Sandra Rodríguez-PeralesMolecular Cytogenetics and Genome Editing Unit, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029, Madrid, Spain.
Mariano BarbacidCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, 28029, Madrid, Spain.
Matthias DrostenMolecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer (CIC), 37007, Salamanca, Spain. mdrosten@usal.es.ORCID http://orcid.org/0000-0002-3205-456X

Funding

Comunidad de Madrid (Community of Madrid) B2017/BMD-3884 iLUNG-CMComunidad de Madrid (Community of Madrid) P2022/BMD-7321/MITIC-CMCONACYT, Gobierno de Mexico 2022-000015-02EXTF-00143EC | ERC | HORIZON EUROPE European Research Council (ERC) ERC-AG/695566 (Theracan)Fundación CientÃ-fica Asociación Española Contra el Cáncer (AECC) EPAEC222641CICSFundación CientÃ-fica Asociación Española Contra el Cáncer (AECC) LABAE20049RODRFundación CientÃ-fica Asociación Española Contra el Cáncer (AECC) LABAE211678DROSFundación CientÃ-fica Asociación Española Contra el Cáncer (AECC) POSTD211274SIMOMEC | Instituto de Salud Carlos III (ISCIII) PI21/01641MEC | Instituto de Salud Carlos III (ISCIII) PI23/01932Ministerio de Ciencia e Innovación (MCIN) BES-2016-079096Ministerio de Ciencia e Innovación (MCIN) PID2020-116705RB-I00Ministerio de Ciencia e Innovación (MCIN) PID2020-119248GB-I00Ministerio de Ciencia e Innovación (MCIN) PRE2019-091685Ministerio de Ciencia, Innovación y Universidades (MCIU) RTI2018-094664-B-I00
6 · The paper itself

Abstract

KRAS mutations are responsible for a quarter of all lung adenocarcinomas. However, the molecular mechanisms linking these mutations and their frequent secondary dosage amplification to tumor formation are still not fully understood. While ample evidence supports a crucial role for the MAPK pathway in tumor development, the primary effectors targeted by this pathway remain largely unexplored. Here we identify the transcriptional repressor Capicua (CIC) as a key target inactivated by KRAS/MAPK signaling in lung adenocarcinoma. We show that genetic loss of CIC recapitulates the phenotypic consequences of amplified KRAS signaling. Genetic disruption of CIC suppressed the requirement for Kras allelic imbalances and accelerated the transformation of bronchiolar Club cells. We also demonstrate that restoring CIC repressor activity impaired proliferation of CIC-deficient tumor cells and reverted resistance to MAPK pathway inhibitors. These results highlight the key role of CIC during lung tumor formation and suggest that selective pressure for effective CIC inactivation favors secondary amplification of KRAS/MAPK signaling in tumor cells.

Indexed as

Adenocarcinoma of LungLung NeoplasmsProto-Oncogene Proteins p21(ras)Repressor ProteinsTumor Suppressor Protein p53AnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansMaleMAP Kinase Signaling SystemMiceAntineoplastic AgentsCIC protein, humanKRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)Repressor ProteinsTrp53 protein, mouseTumor Suppressor Protein p53Allelic ImbalanceDrug ResistanceKRASLung CancerRepression

Identifiers

PMID41219537
PMCPMC12686060

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.